Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

517 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Determining the PASS cut-off points for the FIQR, FASmod and PSD in patients with fibromyalgia: a registry-based study.
Salaffi F, Di Carlo M, Di Franco M, Bianchi G, Bazzichi L, Tirri R, Guiducci S, Gorla R, Atzeni F, Giacomelli R, Di Donato E, Guggino G, Fischetti F, Tirri E, Biasi G, Foti R, Dagna L, Carubbi F, Gremese E, Govoni M, Cutolo M, Iannone F, Lippolis I, Conti F, Tramontano G, Marino V, Farah S, Sarzi-Puttini P; Società Italiana di Reumatologia (SIR). Salaffi F, et al. Among authors: govoni m. Clin Exp Rheumatol. 2023 Jun;41(6):1275-1282. doi: 10.55563/clinexprheumatol/on8j9a. Epub 2023 May 3. Clin Exp Rheumatol. 2023. PMID: 37140611 Free article.
Role of infectious agents in systemic rheumatic diseases.
Amital H, Govoni M, Maya R, Meroni PL, Ori B, Shoenfeld Y, Tincani A, Trotta F, Sarzi-Puttini P, Atzeni F. Amital H, et al. Among authors: govoni m. Clin Exp Rheumatol. 2008 Jan-Feb;26(1 Suppl 48):S27-32. Clin Exp Rheumatol. 2008. PMID: 18570751 Review.
The CC homozygosis of the -174G>C IL-6 polymorphism predicts a lower efficacy of rituximab therapy in rheumatoid arthritis.
Fabris M, Quartuccio L, Lombardi S, Saracco M, Atzeni F, Carletto A, Cimmino M, Fabro C, Pontarini E, Pellerito R, Bambara LM, Sarzi-Puttini P, Cutolo M, Manfredi M, Benucci M, Morassi P, Fischetti F, Padovan M, Govoni M, Curcio F, Tonutti E, De Vita S. Fabris M, et al. Among authors: govoni m. Autoimmun Rev. 2012 Mar;11(5):315-20. doi: 10.1016/j.autrev.2010.06.012. Epub 2010 Oct 23. Autoimmun Rev. 2012. PMID: 20974296
Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients.
Govoni M, Bombardieri S, Bortoluzzi A, Caniatti L, Casu C, Conti F, De Vita S, Doria A, Farina I, Ferraccioli G, Gremese E, Mansutti E, Mosca M, Padovan M, Piga M, Tincani A, Tola MR, Tomietto P, Taglietti M, Trotta F, Valesini G, Zen M, Mathieu A; Italian Society of Rheumatology. Govoni M, et al. Rheumatology (Oxford). 2012 Jan;51(1):157-68. doi: 10.1093/rheumatology/ker310. Epub 2011 Nov 10. Rheumatology (Oxford). 2012. PMID: 22075066
Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry.
Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG, Frati E, Foschi V, Gasparini S, Giardina A, Gremese E, Iannone F, Sebastiani M, Ziglioli T, Biasi D, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Gorla R, Govoni M, Lapadula G, Marchesoni A, Salaffi F, Punzi L, Triolo G, Ferraccioli G. Atzeni F, et al. Among authors: govoni m. Autoimmun Rev. 2012 Dec;12(2):225-9. doi: 10.1016/j.autrev.2012.06.008. Epub 2012 Jul 13. Autoimmun Rev. 2012. PMID: 22796281
The TTTT B lymphocyte stimulator promoter haplotype is associated with good response to rituximab therapy in seropositive rheumatoid arthritis resistant to tumor necrosis factor blockers.
Fabris M, Quartuccio L, Vital E, Pontarini E, Salvin S, Fabro C, Zabotti A, Benucci M, Manfredi M, Ravagnani V, Biasi D, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Bazzicchi L, Saracco M, Pellerito R, Cimmino M, Carraro V, Semeraro A, Schiavon F, Caporali R, Bortolotti R, Govoni M, Fogolari F, Tonutti E, Bombardieri S, Emery P, De Vita S. Fabris M, et al. Among authors: govoni m. Arthritis Rheum. 2013 Jan;65(1):88-97. doi: 10.1002/art.37707. Arthritis Rheum. 2013. PMID: 23001900 Free article.
The 158VV Fcgamma receptor 3A genotype is associated with response to rituximab in rheumatoid arthritis: results of an Italian multicentre study.
Quartuccio L, Fabris M, Pontarini E, Salvin S, Zabotti A, Benucci M, Manfredi M, Biasi D, Ravagnani V, Atzeni F, Sarzi-Puttini P, Morassi P, Fischetti F, Tomietto P, Bazzichi L, Saracco M, Pellerito R, Cimmino M, Schiavon F, Carraro V, Semeraro A, Caporali R, Cavagna L, Bortolotti R, Paolazzi G, Govoni M, Bombardieri S, De Vita S. Quartuccio L, et al. Among authors: govoni m. Ann Rheum Dis. 2014 Apr;73(4):716-21. doi: 10.1136/annrheumdis-2012-202435. Epub 2013 Mar 16. Ann Rheum Dis. 2014. PMID: 23505228
Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database.
Scirè CA, Caporali R, Sarzi-Puttini P, Frediani B, Di Franco M, Tincani A, Sinigaglia L, Sfriso P, Tirri R, Bellis E, Delsante G, Porru G, Salaffi F, Giuggioli D, Rossini M, Todoerti M, Bazzichi L, Govoni M, Gerli R, Raschetti R, Minisola G, Montecucco C, Todesco S; Monitornet project. Scirè CA, et al. Among authors: govoni m. Clin Exp Rheumatol. 2013 Nov-Dec;31(6):857-63. Epub 2013 Aug 26. Clin Exp Rheumatol. 2013. PMID: 23981363 Free article.
517 results